ERBB3 and chordoma: Furthermore, EGFR activation has also been reported, and an European multi-center trial is evaluating the efficacy of afatinib, an ERBB family (EGFR/ERBB1, HER2/ERBB2, ERBB3, and ERBB4) inhibitor, as first-line or later-line treatment in advanced chordoma (NCT03083678).